CAS: 1715-33-9; Prednisolone (Sodium Succinate)

该化合物是一种具有抗炎和免疫抑制特性的合成花生类固醇,是一种具有抗炎和免疫抑制特性的合成花生类固醇,是一种具有抗炎和免疫抑制特性的聚氨酯;是一种含有先聚氮溶液的钠盐,它能增加溶解性和生物利用率,适合亲生管理;这种化合物经常用于临床环境,以管理严重过敏,哮喘和自生素紊乱等条件; 聚氨酯钠在调节免疫反应和减少炎症发方面表现出高度的威力,抑制了炎性调节器的释放; 它通常通过静脉或肌肉内施用,允许迅速采取行动; 该物质的特点是在适当的储存条件下保持稳定,尽管应保护其不受光和水的侵扰; 其致癌性肿瘤学涉及 hepatic 代谢,并含有新陈代谢剂的排泄. 与其他园艺类固醇类相比,潜在的副作用可能包括增加感染的敏感度,液体留存和改变葡萄代谢代谢的代谢性,从而有必要对各种高效的治疗.

结构式图片

相似化合物

53-36-1 52-21-1 71677-45-7

欧盟法规

ECHA物质C&L通报REACH预注册

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-9051302-B2
    优先权日:2008-01-15
    标 题 :Synthesis of resorcylic acid lactones useful as therapeutic agents
    发明人:WINSSINGER NICOLAS; BARLUENGA SOFIA; KARPLUS MARTIN
    权利人:WINSSINGER NICOLAS; BARLUENGA SOFIA; KARPLUS MARTIN; UNIV STRASBOURG
    摘要:Disclosed are macrocyclic compounds of formulae I, I′, II, II′, III, III′, IV, and V, which are analogs of the pochonin resorcylic acid lactones, pharmaceutical compositions comprising the compounds, and methods and uses comprising the compounds for the treatment of diseases mediated by kinases and Heat Shock Protein 90 HSP90.

    专利号:WO-9709067-A1
    优先权日:1995-09-05
    标 题 :Combination of 5-lipoxygenase and leukotriene synthesis inhibitors with glucocorticosteroids
    发明人:BURCHARDT ELMAR-REINHOLD; MUELLER-PEDDINGHAUS REINER
    权利人:BAYER AG; BURCHARDT ELMAR REINHOLD; MUELLER PEDDINGHAUS REINER
    摘要:The combination is disclosed of 5-lipoxygenase inhibitors as direct action lipoxygenase inhibitors (LOI) or of leukotriene synthesis inhibitors (LSI) with glucocorticosteroids (GCS). This combination is suitable for treating and preventing various acute and chronic inflammatory processes, in particular of the respiratory tract, and may therefore be used as a medicament, in particular for treating asthma.

    专利号:US-2021244638-A1
    优先权日:2018-06-05
    标 题:Inhibitors of glycosphingolipid synthesis and methods of use
    发明人:CHATTERJEE SUBROTO B
    权利人:SUBROTO B CHATTERJEE
    摘要:Compositions in the prevention and treatment of skin diseases or associated disorders, inflammation or inflammatory diseases or disorders, include at least one inhibitor of glycosphingolipid synthesis.

    专利号:WO-2024233563-A1
    优先权日:2023-05-09
    标 题:6,6-fused bicyclic amides and compositions for use as 15-prostaglandin dehydrogenase modulators
    发明人:GREENMAN KEVIN LLOYD; WANG HUI-LING; WEIRES NICHOLAS ANTHONY; ALLEN JOHN G; AMEGADZIE ALBERT K; BOURBEAU MATTHEW P; LI KEXUE
    权利人:AMGEN INC
    摘要:The present disclosure provides novel 15-hydroxy-prostaglandin dehydrogenase inhibitors, pharmaceutical compositions comprising such compounds, and methods of using such compounds and compositions in treating 15-hydroxy-prostaglandin dehydrogenase-mediated disease. Also provided are methods of making such compounds and intermediates thereof. The compounds have a structure of Formula (I): or a pharmaceutically acceptable salt thereof; wherein is Formula (i) or Formula (ii) Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (I).

    专利号:US-2024409557-A1
    优先权日:2023-05-09
    标 题 :5,6-fused and 6,6-fused bicyclic alcohols and ethers and compositions for use as 15-prostaglandin dehydrogenase modulators
    发明人:GREENMAN KEVIN LLOYD; PICKRELL ALEXANDER J; LI KEXUE; AMEGADZIE ALBERT K; WANG HUI-LING; WEIRES NICHOLAS ANTHONY; ALLEN JOHN G; BOURBEAU MATTHEW P
    权利人:AMGEN INC
    摘要:The present disclosure provides novel 15-hydroxy-prostaglandin dehydrogenase inhibitors, pharmaceutical compositions comprising such compounds, and methods of using such compounds and compositions in treating 15-hydroxy-prostaglandin dehydrogenase-mediated disease. Also provided are methods of making such compounds and intermediates thereof. The compounds have a general Formula (A).Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula (A).

    专利号:US-10239856-B2
    优先权日:2008-01-15
    标题:Synthesis of resorcylic acid lactones useful as therapeutic agents
    天津市世和科技发展有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.harmonyworld.biz
    电话: 086-22-23697098👤
    📞天津市世和科技发展有限公司 ⚠️参考联系方式

    销售电话:086-22-23697098
    邮箱:info@harmonyworld.biz
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Hayashi S, Akao N, Okamoto K. Meningeal plasma cell granuloma in the early stage of relapsing polychondritis. Rinsho Shinkeigaku. 2017 May 26. doi: 10.5692/clinicalneurol.cn-000975. [Epub ahead of print] doi: 10.20344/amp.7297. Epub 2017 Mar 31. Portuguese. . Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis. Ann Rheum Dis. 2017 May 25. pii: annrheumdis-2017-211123. doi: 10.1136/annrheumdis-2017-211123. [Epub ahead of print] doi: 10.3315/jdcr.2017.1243. eCollection 2017 Mar 31.
    13: Saito A, Takeuchi Y, Kagaya S, Ojima Y, Fukami H, Sato H, Matsuda K, Nagasawa T. Remission Induction Therapy with Rituximab for Microscopic Polyangiitis: A Feasibility Study. Tohoku J Exp Med. 2017;242(1):53-62. doi: 10.1620/tjem.242.53. doi: 10.1097/MD.0000000000006968. doi: 10.1097/MD.0000000000006965. pii: E17. doi: 10.3390/pharmaceutics9020017. Increased risk of hepatitis B virus reactivation in systemic lupus erythematosus patients receiving immunosuppressants: a retrospective cohort study. Lupus. 2017 Jan
    1:961203317711009. doi: 10.1177/0961203317711009. [Epub ahead of print]

    合成参考文献


    摘要:Pharmaceutical Chemistry Journal, 16(63), 1982
    摘要:Kleemann, A.; Engel, J.; Kutscher, B.; Reichert, D., Pharmaceutical Substances[Online], Thieme: Stuttgart, (2003).
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知